Top

Published in:

Open Access 01-12-2017 | Research

Purinergic receptors P2Y12R and P2X7R: potential targets for PET imaging of microglia phenotypes in multiple sclerosis

Authors: Wissam Beaino, Bieneke Janssen, Gijs Kooij, Susanne M. A. van der Pol, B. van Het Hof, Jack van Horssen, Albert D. Windhorst, Helga E. de Vries

Published in: Journal of Neuroinflammation | Issue 1/2017

Abstract

Background

Microglia are major players in the pathogenesis of multiple sclerosis (MS) and may play a dual role in disease progression. The activation status of microglia in vivo is highly dynamic and occurs as a continuum, with the pro-inflammatory and anti-inflammatory phenotypes on either end of this spectrum. Little is known about in vivo dynamics of microglia phenotypes in MS due to the lack of diagnostic tools. Positron emission tomography (PET) imaging is a powerful non-invasive technique that allows real-time imaging of microglia activation phenotypes in the central nervous system, depending on the availability of selective PET tracers. Our objective is to investigate and characterize the expression of the purinergic receptors P2Y12R and P2X7R as potential targets for PET tracer development and subsequent PET imaging in order to evaluate the dynamics of microglia status in vivo.

Methods

We used immunohistochemical analysis to explore the expression of P2Y12R and P2X7R in experimental autoimmune encephalomyelitis (EAE) post-mortem tissues and different stages of well-characterized MS lesions. We evaluated by quantitative real-time polymerase chain reaction the expression of P2Y12R and P2X7R in human polarized microglia, and we performed autoradiography binding assay with radiolabeled P2Y12R and P2X7R antagonists using MS and rat EAE tissues.

Results

Here, we demonstrate that P2X7R is associated with a pro-inflammatory phenotype of human microglia in vitro, and is highly expressed in microglia in MS lesions as well as during the peak of EAE. In contrast, P2Y12R was associated with an anti-inflammatory phenotype in human microglia in vitro and was expressed at lower levels in active inflammatory MS lesions compared to normal-appearing white matter (NAWM) and similarly in EAE, while its expression increased in the remission phase of EAE. Binding of radiolabeled tracers specific for P2Y12R and P2X7R on ex vivo tissues validated the value of these receptors as PET imaging targets for microglia phenotypes in vivo.

Conclusion

Our results suggest that P2Y12R and P2X7R are excellent targets for PET imaging to discriminate distinct microglia phenotypes in MS. Ultimately, this may provide insight into the role of microglia in disease progression and monitor novel treatment strategies to alter microglia phenotype.

Available only for authorised users

Garg N, Smith TW. An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain Behav. 2015;5:e00362. https://doi.org/10.1002/brb3.362 .CrossRefPubMedPubMedCentral

Prinz M, Tay TL, Wolf Y, Jung S. Microglia: unique and common features with other tissue macrophages. Acta Neuropathol. 2014;128:319–31. https://doi.org/10.1007/s00401-014-1267-1 .CrossRefPubMed

Peferoen LAN, Vogel DYS, Ummenthum K, Breur M, Heijnen, Priscilla DAM, Gerritsen WH, et al. Activation status of human microglia is dependent on lesion formation stage and remyelination in multiple sclerosis. J Neuropathol Exp Neurol. 2015;74:48–63. https://doi.org/10.1097/NEN.0000000000000149 .CrossRefPubMed

Vogel DYS, Vereyken EJF, Glim JE, Heijnen PDAM, Moeton M, van der Valk P, et al. Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J Neuroinflammation. 2013;10:35. https://doi.org/10.1186/1742-2094-10-35 .CrossRefPubMedPubMedCentral

Gomez-Nicola D, Perry VH. Microglial dynamics and role in the healthy and diseased brain: a paradigm of functional plasticity. Neuroscientist. 2015;21:169–84. https://doi.org/10.1177/1073858414530512 .CrossRefPubMedPubMedCentral

Parkhurst CN, Gan W. Microglia dynamics and function in the CNS. Curr Opin Neurobiol. 2010;20:595–600. https://doi.org/10.1016/j.conb.2010.07.002.CrossRefPubMedPubMedCentral

Correale J. The role of microglial activation in disease progression. Mult Scler. 2014;20:1288–95. https://doi.org/10.1177/1352458514533230 .CrossRefPubMed

Giunti D, Parodi B, Cordano C, Uccelli A, Kerlero de Rosbo N. Can we switch microglia’s phenotype to foster neuroprotection? Focus on multiple sclerosis. Immunology. 2014;141:328–39. https://doi.org/10.1111/imm.12177 .CrossRefPubMedPubMedCentral

Kettenmann H, Hanisch U, Noda M, Verkhratsky A. Physiology of microglia. Physiol Rev. 2011;91:461–553. https://doi.org/10.1152/physrev.00011.2010 .CrossRefPubMed

10.

Heppner FL, Greter M, Marino D, Falsig J, Raivich G, Hovelmeyer N, et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med. 2005;11:146–52. https://doi.org/10.1038/nm1177 .CrossRefPubMed

11.

Kotter MR, Li W, Zhao C, Franklin RJM. Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation. J Neurosci. 2006;26:328–32. https://doi.org/10.1523/JNEUROSCI.2615-05.2006 .CrossRefPubMed

12.

Filbin MT. Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS. Nat Rev Neurosci. 2003;4:703–13. https://doi.org/10.1038/nrn1195 .CrossRefPubMed

13.

Butovsky O, Ziv Y, Schwartz A, Landa G, Talpalar AE, Pluchino S, et al. Microglia activated by IL-4 or IFN-gamma differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells. Mol Cell Neurosci. 2006;31:149–60. https://doi.org/10.1016/j.mcn.2005.10.006 .CrossRefPubMed

14.

Tierney JB, Kharkrang M, La Flamme AC. Type II-activated macrophages suppress the development of experimental autoimmune encephalomyelitis. Immunol Cell Biol. 2009;87:235–40. https://doi.org/10.1038/icb.2008.99 .CrossRefPubMed

15.

Airas L, Rissanen E, Rinne JO. Imaging neuroinflammation in multiple sclerosis using TSPO-PET. Clin Transl Imaging. 2015;3:461–73. https://doi.org/10.1007/s40336-015-0147-6 .CrossRefPubMedPubMedCentral

16.

Vivash L, O'Brien TJ. Imaging microglial activation with TSPO PET: lighting up neurologic diseases? J Nucl Med. 2016;57:165–8. https://doi.org/10.2967/jnumed.114.141713 .CrossRefPubMed

17.

Yu Y, Ugawa S, Ueda T, Ishida Y, Inoue K, Kyaw Nyunt A, et al. Cellular localization of P2X7 receptor mRNA in the rat brain. Brain. 2008;1194:45–55. https://doi.org/10.1016/j.brainres.2007.11.064 .CrossRef

18.

Clark AK, Staniland AA, Marchand F, Kaan TKY, McMahon SB, Malcangio M. P2X7-dependent release of interleukin-1 beta and nociception in the spinal cord following lipopolysaccharide. J Neurosci. 2010;30:573–82. https://doi.org/10.1523/JNEUROSCI.3295-09.2010 .CrossRefPubMedPubMedCentral

19.

Monif M, Burnstock G, Williams DA. Microglia: proliferation and activation driven by the P2X7 receptor. Int J Biochem Cell Biol. 2010;42:1753–6. https://doi.org/10.1016/j.biocel.2010.06.021 .CrossRefPubMed

20.

Bhattacharya A, Biber K. The microglial ATP-gated ion channel P2X7 as a CNS drug target. Glia. 2016;64:1772–87. https://doi.org/10.1002/glia.23001.CrossRefPubMed

21.

Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, et al. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci. 2014;17:131–43. https://doi.org/10.1038/nn.3599 .CrossRefPubMed

22.

Mildner A, Huang H, Radke J, Stenzel W, Priller J. P2Y12 receptor is expressed on human microglia under physiological conditions throughout development and is sensitive to neuroinflammatory diseases. Glia. 2017;65:375–87. https://doi.org/10.1002/glia.23097 .CrossRefPubMed

23.

Janssen B, Vugts DJ, Funke U, Spaans A, Schuit RC, Kooijman E, et al. Synthesis and initial preclinical evaluation of the P2X7 receptor antagonist [¹¹C]A-740003 as a novel tracer of neuroinflammation. J Label Compd Radiopharm. 2014;57:509–16. https://doi.org/10.1002/jlcr.3206 .CrossRef

24.

Janssen B, Vugts DJ, Funke U, Perry S, Kruijer, Dolle F, Bormans G, et al. Synthesis of the first carbon-11 labelled P2Y12 receptor antagonist for PET imaging of microglial activation in neuroinflammation. J Label Compd Radiopharm. 2015;58:S1–S74. https://doi.org/10.1002/jlcr.3302_1 .CrossRef

25.

de Vries HE, JJA H, Honing H, de Lavalette CR, SMA v d P, Hooijberg E, et al. Signal-regulatory protein -CD47 interactions are required for the transmigration of monocytes across cerebral endothelium. J Immunol. 2002;168:5832–9. https://doi.org/10.4049/jimmunol.168.11.5832 .CrossRefPubMed

26.

Garcia-Vallejo JJ, van Dijk W, van Het Hof B, van Die I, Engelse MA, Hinsbergh V, Victor WM, Gringhuis SI. Activation of human endothelial cells by tumor necrosis factor-alpha results in profound changes in the expression of glycosylation-related genes. J Cell Physiol. 2006;206:203–10. https://doi.org/10.1002/jcp.20458 .CrossRefPubMed

27.

Rodrigues RJ, Tomé AR, Cunha RA. ATP as a multi-target danger signal in the brain. Front Neurosci. 2015;9:148. https://doi.org/10.3389/fnins.2015.00148 .CrossRefPubMedPubMedCentral

28.

Lin C, Edelson BT. New insights into the role of IL-1β in experimental autoimmune encephalomyelitis and multiple sclerosis. J Immunol. 2017;198:4553–60. https://doi.org/10.4049/jimmunol.1700263 .CrossRefPubMed

29.

Matute C, Torre I, Perez-Cerda F, Perez-Samartin A, Alberdi E, Etxebarria E, et al. P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. J Neurosci. 2007;27:9525–33. https://doi.org/10.1523/JNEUROSCI.0579-07.2007 .CrossRefPubMed

30.

Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, Bountra C, et al. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 2006;6:12. https://doi.org/10.1186/1471-2377-6-12.CrossRefPubMedPubMedCentral

31.

Ruuls SR, Sedgwick JD. Cytokine-directed therapies in multiple sclerosis and experimental autoimmune encephalomyelitis. Immunol Cell Biol. 1998;76:65–73. https://doi.org/10.1046/j.1440-1711.1998.00715.x .CrossRefPubMed

32.

Zrzavy T, Hametner S, Wimmer I, Butovsky O, Weiner HL, Lassmann H. Loss of ‘homeostatic’ microglia and patterns of their activation in active multiple sclerosis. Brain. 2017;140:1900–13. https://doi.org/10.1093/brain/awx113 .CrossRefPubMed

33.

Moore CS, Ase AR, Kinsara A, Rao VTS, Michell-Robinson M, Leong SY, et al. P2Y12 expression and function in alternatively activated human microglia. Neurol Neuroimmunol Neuroinflamm. 2015;2:e80. https://doi.org/10.1212/NXI.0000000000000080.CrossRefPubMedPubMedCentral

34.

Bartlett R, Stokes L, Sluyter R. The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease. Pharmacol Rev. 2014;66:638–75. https://doi.org/10.1124/pr.113.008003 .CrossRefPubMed

35.

Ory D, Celen S, Gijsbers R, van den Haute C, Postnov A, Koole M, et al. Preclinical evaluation of a P2X7 receptor-selective radiotracer: PET studies in a rat model with local overexpression of the human P2X7 receptor and in nonhuman primates. J Nucl Med. 2016;57:1436–41. https://doi.org/10.2967/jnumed.115.169995 .CrossRefPubMed

Title: Purinergic receptors P2Y12R and P2X7R: potential targets for PET imaging of microglia phenotypes in multiple sclerosis
Authors: Wissam Beaino
Bieneke Janssen
Gijs Kooij
Susanne M. A. van der Pol
B. van Het Hof
Jack van Horssen
Albert D. Windhorst
Helga E. de Vries
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Journal of Neuroinflammation / Issue 1/2017
Electronic ISSN: 1742-2094
DOI: https://doi.org/10.1186/s12974-017-1034-z

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Purinergic receptors P2Y12R and P2X7R: potential targets for PET imaging of microglia phenotypes in multiple sclerosis

Abstract

Background

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2017

The Alzheimer’s disease risk factors apolipoprotein E and TREM2 are linked in a receptor signaling pathway

BAFF Index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset

Microglial-derived microparticles mediate neuroinflammation after traumatic brain injury

Acute maternal oxidant exposure causes susceptibility of the fetal brain to inflammation and oxidative stress

Donepezil suppresses intracellular Ca2+ mobilization through the PI3K pathway in rodent microglia

EZH2 suppression in glioblastoma shifts microglia toward M1 phenotype in tumor microenvironment